Abstract
Molecular mechanisms behind the defects in insulin production and secretion associated with antihuman immunodeficiency virus (anti-HIV) therapy and the development of HIV-associated lipodystrophy syndrome (HALS) are discussed in this article. Data suggesting insulin resistance on the beta cell and defects in first-phase insulin release of HALS patients are presented. Hepatic extraction of insulin, nonglucose insulin secretagogues and insulin-like growth factor release may exert influence on the demand of circulating insulin and on insulin secretion in HIV-infected patients. Finally, the paucity in understanding the incretin effects in HIV and HIV therapy in relation to insulin secretion is highlighted.
| Original language | English |
|---|---|
| Journal | Endocrinology & Metabolism Clinics of North America |
| Volume | 43 |
| Issue number | 3 |
| Pages (from-to) | 697-708 |
| Number of pages | 12 |
| ISSN | 0889-8529 |
| DOIs | |
| Publication status | Published - Sept 2014 |
Keywords
- Carbamates
- HIV Protease Inhibitors
- HIV-Associated Lipodystrophy Syndrome
- Humans
- Indinavir
- Insulin
- Insulin Resistance
- Insulin-Secreting Cells
- Nelfinavir
- Ritonavir
- Sulfonamides
